z-logo
Premium
Design, Synthesis and Evaluation of Antidepressant Activity of Novel 2‐Methoxy 1, 8 Naphthyridine 3‐Carboxamides as 5‐ HT 3 Receptor Antagonists
Author(s) -
Mahesh Radhakrishnan,
Dhar Arghya Kusum,
Jindal Ankur,
Bhatt Shvetank
Publication year - 2014
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12271
Subject(s) - pharmacophore , behavioural despair test , chemistry , piperazine , antagonism , antidepressant , pharmacology , agonist , receptor , nicotinamide , 5 ht receptor , stereochemistry , serotonin , biochemistry , medicine , enzyme , organic chemistry , hippocampus
A series of novel 1,8‐naphthyridine‐3‐carboxamides as 5‐ HT 3 receptor antagonists were synthesized with an intention to explore the antidepressant activity of these compounds. The title carboxamides were designed using ligand‐based approach keeping in consideration the structural requirement of the pharmacophore of 5‐ HT 3 receptor antagonists. The compounds were synthesized using appropriate synthetic route from the starting material nicotinamide. 5‐ HT 3 receptor antagonism of all the compounds, which was denoted in the form of p A 2 value, was determined in longitudinal muscle myenteric plexus preparation from guinea‐pig ileum against 5‐ HT 3 agonist, 2‐methyl‐5‐ HT . Compound 8g (2‐methoxy‐1, 8‐naphthyridin‐3‐yl) (2‐methoxy phenyl piperazine‐1‐yl) methanone was identified as the most active compound, which expressed a p A 2 value of 7.67. The antidepressant activity of all the compounds was examined in mice model of forced swim test ( FST ); importantly, none of the compounds was found to cause any significant changes in the locomotor activity of mice at the tested dose levels. In FST , the compounds with considerably higher p A 2 value exhibited promising antidepressant‐like activity, whereas compounds with lower p A 2 value did not show antidepressant‐like activity as compared to the control group.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here